Filing Details

Accession Number:
0001933414-23-000062
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-11 19:11:30
Reporting Period:
2023-08-10
Accepted Time:
2023-08-11 19:11:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1933414 Mineralys Therapeutics Inc. MLYS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1672659 Malcom David Rodman 150 N. Radnor Chester Road,
Suite F200
Radnor PA 19087
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-10 74,625 $0.54 74,625 No 4 M Direct
Common Stock Disposition 2023-08-10 74,625 $13.16 0 No 4 S Direct
Common Stock Acquisiton 2023-08-11 80,909 $0.54 80,909 No 4 M Direct
Common Stock Disposition 2023-08-11 80,909 $12.81 0 No 4 S Direct
Common Stock Acquisiton 2023-08-11 76,182 $1.08 76,182 No 4 M Direct
Common Stock Disposition 2023-08-11 76,182 $12.81 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2023-08-10 74,625 $0.00 74,625 $0.54
Common Stock Stock Option Disposition 2023-08-11 80,909 $0.00 80,909 $0.54
Common Stock Stock Option Disposition 2023-08-11 76,182 $0.00 76,182 $1.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
166,202 2031-03-11 No 4 M Direct
85,293 2031-03-11 No 4 M Direct
228,548 2031-07-11 No 4 M Direct
Footnotes
  1. The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $13.00 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  2. The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $12.39 to $13.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  3. Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
  4. The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
  5. Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
  6. The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.